HomeCompareAPLIF vs VIG

APLIF vs VIG: Dividend Comparison 2026

APLIF yields 18181.82% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APLIF wins by $20382968138483965952.00M in total portfolio value
10 years
APLIF
APLIF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20382968138483965952.00M
Annual income
$20,164,798,479,641,134,000,000,000.00
Full APLIF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — APLIF vs VIG

📍 APLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPLIFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APLIF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APLIF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLIF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$17,140,078,707,694,964,000,000,000.00/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, APLIF beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLIF + VIG for your $10,000?

APLIF: 50%VIG: 50%
100% VIG50/50100% APLIF
Portfolio after 10yr
$10191484069241982976.00M
Annual income
$10,082,399,239,820,567,000,000,000.00/yr
Blended yield
98.93%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLIF buys
0
VIG buys
0
No recent congressional trades found for APLIF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPLIFVIG
Forward yield18181.82%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$20382968138483965952.00M$32.4K
Annual income after 10y$20,164,798,479,641,134,000,000,000.00$179.15
Total dividends collected$20368560651224936448.00M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: APLIF vs VIG ($10,000, DRIP)

YearAPLIF PortfolioAPLIF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$1,828,882$1,818,181.82$11,304$163.92+$1.82MAPLIF
2$312,726,966$310,770,062.56$12,759$166.33+$312.71MAPLIF
3$49,997,862,140$49,663,244,286.24$14,382$168.52+$49997.85MAPLIF
4$7,474,070,205,933$7,420,572,493,443.65$16,192$170.52+$7474070.19MAPLIF
5$1,044,712,232,322,833$1,036,714,977,202,484.10$18,210$172.34+$1044712232.30MAPLIF
6$136,547,911,758,351,100$135,430,069,669,765,680.00$20,460$173.98+$136547911758.33MAPLIF
7$16,689,313,388,956,088,000$16,543,207,123,374,653,000.00$22,968$175.48+$16689313388956.07MAPLIF
8$1,907,542,220,817,720,100,000$1,889,684,655,491,537,200,000.00$25,763$176.83+$1907542220817720.25MAPLIF
9$203,896,877,423,206,970,000,000$201,855,807,246,932,000,000,000.00$28,878$178.05+$203896877423206976.00MAPLIF
10$20,382,968,138,483,967,000,000,000$20,164,798,479,641,134,000,000,000.00$32,350$179.15+$20382968138483965952.00MAPLIF

APLIF vs VIG: Complete Analysis 2026

APLIFStock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Full APLIF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this APLIF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLIF vs SCHDAPLIF vs JEPIAPLIF vs OAPLIF vs KOAPLIF vs MAINAPLIF vs DGROAPLIF vs NOBLAPLIF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.